Syndax Pharmaceuticals Inc. has announced new compensation terms under its 2023 Inducement Plan, granting inducement awards to seven new employees. The awards include options to purchase up to 48,600 shares of common stock. The stock options will vest over a period of four years, with 25% of the shares vesting on the first anniversary of the vesting commencement date. Subsequently, 1/48th of the shares will vest monthly over the next 36 months, contingent upon the continuation of the employees' service with the company. This plan aims to align employee interests with the company's long-term success.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.